[Value of systemic streptokinase therapy in thromboembolism diseases].
Among 27,756 cases with stationary treatment 1,532 patients were found in whom a systemic fibrinolysis therapy was taken into consideration. Under strict attention to indications and contraindications 173 patients were treated with streptokinase. The rate of treatment failures in peripheral arterial obstructions was 46%, in venous thromboses 29%. The lethality of pulmonary embolisms could be decreased significantly, in acute myocardial infarction however, it could not be reduced. In 10% of the cases we observed severe therapeutic complications. The systemic streptokinase therapy is therefore a certainly effective, but also high-risk method of treatment, which must be performed by an experienced physician.
D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D011655:Pulmonary Embolism / Q000188:drug therapy; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use*; D013923:Thromboembolism / Q000188:drug therapy*; D013924:Thrombophlebitis / Q000188:drug therapy
D013300:Streptokinase
Zum Stellenwert der systemischen Streptokinasetherapie bei thromboembolischen Erkrankungen.